q5y40y.o.52y.o.depression≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorovariancancerdyslipidemiainsufficientevidenceforscreeningcommunity-dwelling,postmenopausalwomenaromataseinhibitorsherpeszoster3%tobaccouse≥ 126mg/dLaspirin≥5.7%≥ 100mg/dLHepatitisCq2y≥20%womenage 55-64 y.o.HIVraloxifene≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors60y.o.≥6.5%2 doses,2-6monthsapartFractureRiskAssessmentToolmultidoseinitial series,then 1 doseat 2-6monthspneumococcalanxietycolorectalcancer≥ 200mg/dLq3yoverweight/ obesity< 60y.o.65y.o.Gailmodelq1y1 dose; 2doses (2-6monthsapart) ifimmunocompdiabeteshypertensionTimedup andgo testTyrer-Cuzickmodelstatinbreastcancer40-59 y.o.,ASCVD ≥10%, lowbleeding riskdementiaPREVENTequationcardiovasculardiseaseq15yHepatitisB40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factortamoxifen≤q2ylungcancerq1-2ymammogrambased on lifeexpectancy /health statushormonetherapy50y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorscervicalcancer40-70 y.o.,ASCVD ≥10%, lowbleeding risk75y.o.q1ymammogramq5y40y.o.52y.o.depression≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorovariancancerdyslipidemiainsufficientevidenceforscreeningcommunity-dwelling,postmenopausalwomenaromataseinhibitorsherpeszoster3%tobaccouse≥ 126mg/dLaspirin≥5.7%≥ 100mg/dLHepatitisCq2y≥20%womenage 55-64 y.o.HIVraloxifene≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors60y.o.≥6.5%2 doses,2-6monthsapartFractureRiskAssessmentToolmultidoseinitial series,then 1 doseat 2-6monthspneumococcalanxietycolorectalcancer≥ 200mg/dLq3yoverweight/ obesity< 60y.o.65y.o.Gailmodelq1y1 dose; 2doses (2-6monthsapart) ifimmunocompdiabeteshypertensionTimedup andgo testTyrer-Cuzickmodelstatinbreastcancer40-59 y.o.,ASCVD ≥10%, lowbleeding riskdementiaPREVENTequationcardiovasculardiseaseq15yHepatitisB40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factortamoxifen≤q2ylungcancerq1-2ymammogrambased on lifeexpectancy /health statushormonetherapy50y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorscervicalcancer40-70 y.o.,ASCVD ≥10%, lowbleeding risk75y.o.q1ymammogram

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. q5y
  2. 40 y.o.
  3. 52 y.o.
  4. depression
  5. ≥ 140 mg/dL
  6. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  7. ovarian cancer
  8. dyslipidemia
  9. insufficient evidence for screening
  10. community-dwelling, postmenopausal women
  11. aromatase inhibitors
  12. herpes zoster
  13. 3%
  14. tobacco use
  15. ≥ 126 mg/dL
  16. aspirin
  17. ≥ 5.7%
  18. ≥ 100 mg/dL
  19. Hepatitis C
  20. q2y
  21. ≥ 20%
  22. women age 55-64 y.o.
  23. HIV
  24. raloxifene
  25. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  26. 60 y.o.
  27. ≥ 6.5%
  28. 2 doses, 2-6 months apart
  29. Fracture Risk Assessment Tool
  30. multidose initial series, then 1 dose at 2-6 months
  31. pneumococcal
  32. anxiety
  33. colorectal cancer
  34. ≥ 200 mg/dL
  35. q3y
  36. overweight / obesity
  37. < 60 y.o.
  38. 65 y.o.
  39. Gail model
  40. q1y
  41. 1 dose; 2 doses (2-6 months apart) if immunocomp
  42. diabetes
  43. hypertension
  44. Timed up and go test
  45. Tyrer-Cuzick model
  46. statin
  47. breast cancer
  48. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  49. dementia
  50. PREVENT equation
  51. cardiovascular disease
  52. q15y
  53. Hepatitis B
  54. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  55. tamoxifen
  56. ≤ q2y
  57. lung cancer
  58. q1-2y mammogram based on life expectancy / health status
  59. hormone therapy
  60. 50 y.o.
  61. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  62. cervical cancer
  63. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  64. 75 y.o.
  65. q1y mammogram